BMO Capital Cuts Price Target as Tokai Pharma (TKAI) Stops ARMOR2 Trial Enrollment

August 23, 2016 7:40 AM EDT
Get Alerts TKAI Hot Sheet
Price: $1.11 +6.73%

Rating Summary:
    3 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade TKAI Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

BMO Capital maintained a Market Perform rating on Tokai Pharmaceuticals (NASDAQ: TKAI), and cut the price target to $1.15 (from $1.70), following the company stops enrollment for the Phase II ARMOR2 expansion trial. Additionally, the Phase II study evaluating galeterone in mCRPC patients who rapidly progress on either enzalutamide or abiraterone will not be initiated.

Analyst Do Kim commented, "We are lowering our TP to $1.15 from $1.70, following 2Q16 actuals and as enrollment for the Phase II ARMOR2 expansion trial is halted. We expect TKAI shares to reflect the cash balance, less the expected burn. Tokai will also not proceed with the Phase II trial evaluating galeterone in mCRPC patients with acquired resistance to enzalutamide or abiraterone."

For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.

Shares of Tokai Pharmaceuticals closed at $1.36 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

BMO Capital

Add Your Comment